ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -2 مورد

Allopurinol: Pediatric drug information

Allopurinol: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Allopurinol: Drug information" and "Allopurinol: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Aloprim;
  • Zyloprim [DSC]
Brand Names: Canada
  • AG-Allopurinol;
  • APO-Allopurinol;
  • GEN-Allopurinol;
  • JAMP-Allopurinol;
  • Mar-Allopurinol
Therapeutic Category
  • Antigout Agent;
  • Uric Acid Lowering Agent
Dosing: Pediatric

Dosage guidance:

Safety: Before use, consider testing for the HLA-B*5801 allele in patients at elevated risk for developing severe cutaneous adverse reactions (SCAR) (including Korean patients with CKD ≥ stage 3 and all patients of Han Chinese or Thai descent). A negative HLA-B*5801 genetic test does not entirely rule out the possibility of allopurinol-associated SCAR or other forms of hypersensitivity (Ref).

Dosing: Dosing presenting in multiple formats (mg/m2/dose, mg/m2/day, mg/kg/day, and a fixed mg dose); take extra precautions to ensure accuracy.

Hyperuricemia associated with inborn errors of purine metabolism

Hyperuricemia associated with inborn errors of purine metabolism (Lesch-Nyhan syndrome): Limited data available: Oral: Infants, Children, and Adolescents: Initial: 5 to 10 mg/kg/day; adjust dose to maintain a high-normal serum uric acid concentration and a urinary uric acid/creatinine ratio <1; reported range: 3.7 to 9.7 mg/kg/day; usual maximum daily dose: 600 mg/day (Ref).

Management of hepatotoxicity, non-hepatic GI toxicity, and/or inadequate myelosuppression associated with 6-mercaptopurine maintenance therapy for acute lymphoblastic leukemia

Management of hepatotoxicity, non-hepatic GI toxicity, and/or inadequate myelosuppression associated with 6-mercaptopurine maintenance therapy for acute lymphoblastic leukemia: Limited data available: Note: In clinical trials, allopurinol was administered at the same time as 6-mercaptopurine.

Fixed dosing: Infants, Children, and Adolescents:

≤30 kg: Oral: 50 mg daily (Ref).

>30 kg: Oral: 100 mg daily (Ref).

BSA-directed dosing: Infants, Children, and Adolescents: Oral: Initial: 50 mg/m2 daily; may increase dose to 100 mg/m2 daily after 4 weeks if erythrocyte levels of thioguanine nucleotides <200 nmol/mmol Hb. Maximum reported daily dose: 100 mg/day (Ref).

Recurrent calcium oxalate renal stones

Recurrent calcium oxalate renal stones (including glycogen storage disease): Limited data available: Oral: Children and Adolescents: 4 to 10 mg/kg/day in divided doses 3 to 4 times daily; maximum daily dose: 300 mg/day (Ref).

Tumor lysis syndrome, prevention of hyperuricemia associated with malignancy

Tumor lysis syndrome, prevention of hyperuricemia associated with malignancy: Maintain adequate hydration; begin allopurinol 1 to 3 days before initiation of induction chemotherapy; may continue for 3 to 7 days after chemotherapy (Ref); doses >300 mg/day should be administered in divided doses:

Oral: Infants, Children, and Adolescents:

BSA-based dosing: Oral: 50 to 100 mg/m2 every 8 to 12 hours; maximum daily dose: 800 mg/day (Ref).

Weight-directed dosing: Oral: 10 mg/kg/day divided every 8 hours; maximum daily dose: 800 mg/day (Ref).

IV: Note: For patients unable to tolerate oral therapy (BSA-directed dosing):

Infants, Children, and Adolescents: 200 to 400 mg/m2/day in 1 to 4 divided doses; maximum daily dose: 600 mg/day (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians:

Tumor lysis syndrome, prevention of hyperuricemia associated with malignancy: Oral, IV:

Altered kidney function: There are no dosage adjustments provided in the manufacturer's labeling; some experts recommend reducing dose to 50% of normal dose in patients with kidney impairment (Ref); however, others suggest that dosage adjustment is not always utilized in patients with tumor lysis syndrome or hyperuricemia associated with malignancy (Ref).

Hemodialysis: Allopurinol and oxypurinol are dialyzable. There are no dosage adjustments provided in the manufacturer's labeling. Based on adult information, dosage adjustment may be necessary; evaluate risk versus benefits in pediatric patients (Ref).

Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer's labeling. Based on adult information, dosage adjustment may be necessary; evaluate risk versus benefits in pediatric patients (Ref).

Other indications:

Altered kidney function (Ref): Oral, IV:

GFR 30 to 50 mL/minute/1.73 m2: Administer 50% of normal dose.

GFR 10 to 29 mL/minute/1.73 m2: Administer 50% of normal dose.

GFR <10 mL/minute/1.73 m2: Administer 30% of normal dose.

Hemodialysis (intermittent): Allopurinol and oxypurinol are dialyzable. Administer 30% of normal dose (Ref).

Peritoneal dialysis: Administer 30% of normal dose (Ref).

Continuous renal replacement therapy (CRRT): Administer 50% of normal dose (Ref).

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Allopurinol: Drug information")

Dosage guidance:

Safety: Before use, test for the HLA-B*5801 allele in patients at elevated risk for developing severe cutaneous adverse reactions (SCAR) (patients of Asian [eg, Korean, Han Chinese, Thai] and African descent) (Ref). A negative HLA-B*5801 genetic test does not entirely rule out the possibility of allopurinol-associated SCAR or other forms of hypersensitivity (Ref). Avoid use in any patient testing positive for the allele (Ref).

Gout, treatment

Gout, treatment (chronic urate-lowering therapy): Oral: Note: Urate-lowering therapy may be initiated during a gout flare or after the flare subsides; concomitant pharmacologic prophylaxis with colchicine, NSAIDS, or a glucocorticoid is recommended for at least the first 3 to 6 months to decrease flare activity (Ref).

Initial: 100 mg once daily (Ref).

Dosage adjustments: Titrate in 100 mg increments every 2 to 4 weeks to achieve the desired serum uric acid level (Ref).

Maintenance: Doses ≥300 mg/day are usually needed to reach the desired uric acid target; doses up to 800 mg/day may be required (Ref).

Maximum: 800 mg/day

Frequency of administration: Once daily in a single dose or in 2 or 3 divided doses. Note: The manufacturer's labeling recommends doses >300 mg be given in divided doses; however, most experts prescribe a single daily dose, regardless of total dose administered, except during a brief period (eg, when initiating or titrating therapy) when divided doses may help improve GI tolerability (Ref).

Nephrolithiasis, prevention of recurrent calcium or uric acid stones

Nephrolithiasis, prevention of recurrent calcium or uric acid stones:

Due to calcium oxalate stones: Patients with hyperuricosuria (who continue to have active disease despite attempted dietary modification): Oral: 300 mg once daily or in 2 or 3 divided doses (Ref).

Due to uric acid stones (off-label use): Oral: 300 mg once daily or in 2 or 3 divided doses; use is reserved for patients who continue to have active disease despite urinary alkalinization therapy and increased hydration (Ref).

Tumor lysis syndrome, prevention of hyperuricemia associated with malignancy

Tumor lysis syndrome, prevention of hyperuricemia associated with malignancy:

Note: For prevention in patients at intermediate risk for tumor lysis syndrome (TLS) with uric acid levels <8 mg/dL (476 micromole/L) (Ref). Aggressive IV hydration should always be initiated prior to cytotoxic therapy in patients at elevated risk for TLS (Ref). If HLA-B*5801 genetic testing in patients at elevated risk of developing severe cutaneous adverse reactions is not feasible (eg, urgent need for chemotherapy), consider alternative agent (eg, rasburicase) (Ref).

Oral: 100 mg/m2/dose every 8 hours (maximum: 800 mg/day). Begin therapy 1 to 2 days before the start of induction chemotherapy and may continue until normalization of laboratory evidence of TLS (eg, serum uric acid, serum LDH) or resolution of TLS risk (Ref).

IV: 200 to 400 mg/m2/day, given in a single daily dose or in 2 or 3 divided doses (maximum: 600 mg/day). Begin therapy 1 to 2 days before the start of induction chemotherapy and may continue until normalization of laboratory evidence of TLS (eg, serum uric acid, serum LDH) or resolution of TLS risk (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Renal impairment, particularly when a higher allopurinol starting dose and/or concomitant diuretics are used, is a risk factor for allopurinol hypersensitivity syndrome (AHS), a rare but potentially life-threatening systemic syndrome (Ref). In addition, the HLA-B*5801 allele is associated with an increased risk of allopurinol-induced severe cutaneous adverse reactions; patients of Korean, Han Chinese, or Thai descent are at increased risk for carrying this allele. Avoid allopurinol in any patient testing positive for this allele (Ref).

To minimize the risk of AHS in patients with renal impairment (in the absence of the HLA-B*5801 allele or in those not at high risk for carrying this allele), the following dosage adjustments are recommended:

Gout, treatment (chronic urate-lowering therapy): Oral:

Altered kidney function:

eGFR >60 mL/minute: No dosage adjustment necessary (Ref).

eGFR ≤60 mL/minute:

Initial: <100 mg daily (Ref); to lower the risk of AHS, some experts recommend not exceeding an initial dose of ~1.5 mg of allopurinol per mL/minute of eGFR (eg, for an eGFR of 50 mL/minute/1.73 m2, the initial dose should not exceed 75 mg daily; see table for suggested initial doses) (Ref).

Allopurinol: Suggested Initial Doses in Kidney Impairmenta

eGFR mL/minute/1.73 m2

Suggested initial dose

aACR (FitzGerald 2020a); Perez-Ruiz 2022; Stamp 2012; Vargas-Santos 2017.

>30 to 60

50 mg daily

>15 to 30

50 mg every other day

5 to 15

50 mg twice weekly

<5

50 mg once weekly

Titration and maintenance: Gradually increase dose in ≤100 mg/day increments every 2 to 4 weeks; use of lower dose increments (ie, ≤50 mg/day) and longer intervals (ie, ≥4 weeks) may be preferred (Ref). Some experts delay the initial dose increase for 1 to 2 months until after peak risk for AHS has passed (Ref). Titrate to the minimum daily dose necessary to achieve goal urate-lowering effect. Doses >300 mg daily may be considered with appropriate patient education and monitoring for potential toxicity (eg, rash, pruritus, elevated transaminases) (Ref). If desired serum uric acid level cannot be achieved, conversion to an alternative agent may be considered (Ref).

Hemodialysis, intermittent (thrice weekly): Dialyzable (oxypurinol): ~39% to 50% (Ref).

Initial: 100 mg 3 times weekly administered post-dialysis (Ref).

Titration and maintenance: Gradually increase dose in ≤50 mg/day increments (eg, 150 mg 3 times weekly) every 2 to 5 weeks. Some experts delay the initial dose increase for 1 to 2 months until after peak risk for AHS has passed (Ref). Titrate to the minimum dose necessary to achieve goal urate-lowering effect (Ref). Doses >300 mg daily may be considered with appropriate patient education and monitoring for potential toxicity (eg, rash, pruritus, elevated transaminases) (Ref); doses up to ~400 mg daily have been reported (Ref).

Peritoneal dialysis:

Initial: 50 mg daily; gradually increase dose in ≤50 mg/day increments every 2 to 5 weeks; titrate to the minimum daily dose necessary to achieve goal urate-lowering effect (Ref). Some experts delay the initial dose increase for 1 to 2 months until after peak risk for AHS has passed (Ref). Doses >300 mg daily may be considered with appropriate patient education and monitoring for potential toxicity (eg, rash, pruritus, elevated transaminases) (Ref).

Nephrolithiasis, prevention of recurrent calcium or uric acid stones: Oral: Use a lower initial dose with gradual titration (Ref); for dosing guidance refer to gout treatment renal impairment dosing recommendations; not to exceed usual adult dose for nephrolithiasis.

Tumor lysis syndrome, prevention: IV, Oral: Dosage reduction of 50% is recommended in renal impairment (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note: Allopurinol is primarily metabolized by the liver through oxidation into the active metabolite, oxypurinol; parent drug and oxypurinol are excreted in the urine (Ref). The HLA-B*5801 allele is associated with an increased risk of allopurinol-induced severe cutaneous adverse reactions; patients of Korean, Han Chinese, or Thai descent are at increased risk for carrying this allele (Ref). Avoid allopurinol in any patient testing positive for this allele (Ref).

Liver impairment prior to treatment initiation:

Initial or dose titration in patients with preexisting liver cirrhosis :

Child-Turcotte-Pugh Class A to C: IV, Oral: No dosage adjustment necessary (Ref).

Liver impairment developing in patients already receiving allopurinol :

Acute worsening of hepatic function (eg, requiring hospitalization):

Child-Turcotte-Pugh Class A to C: IV, Oral: No dosage adjustment necessary; however, if allopurinol-induced liver injury is confirmed or suspected, permanently discontinue allopurinol therapy secondary to high risk of mortality (Ref).

Adverse Reactions (Significant): Considerations
Acute gout attacks

Acute gout attacks have been reported during the early stages of allopurinol administration even when normal or optimal serum uric acid levels have been attained. Gout attacks generally decrease in duration and severity after several months of urate-lowering therapy (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Decrease in serum urate leads to the dissolution of monosodium urate crystal deposits and dispersion of crystals, causing gout flares (Ref).

Onset: Varied; most likely to occur within first 6 months of treatment (Ref); risk is lower after 1 year of treatment (Ref).

Risk factors:

• Early in course of treatment (Ref)

• Initiating urate-lowering treatment without concurrent gout flare prophylaxis (Ref)

• Withdrawal of anti-inflammatory gout flare prophylaxis (Ref)

• Uric acid >6 mg/dL during treatment (Ref)

• Rapid decreases and/or greater reduction in uric acid (Ref)

• Persistence of tophi (Ref)

Hypersensitivity reactions (delayed) and hepatotoxicity

Allopurinol is associated with a variety of delayed hypersensitivity reactions (often termed allopurinol hypersensitivity syndrome [AHS]), ranging from mild maculopapular rash to severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) (Ref).

Most cases of acute hepatotoxicity with allopurinol are associated with DRESS and AHS (Ref). Hepatotoxicity may rarely occur without any features of DRESS (Ref). Liver enzyme elevations are usually hepatocellular or mixed, but may be cholestatic (Ref).

Mechanism: Immunologic; delayed hypersensitivity reactions, including maculopapular eruptions and SCARs are T-cell-mediated (Ref).

Onset:

Delayed hypersensitivity reactions: Varied; usually occur 3 to 9 weeks after initiation (Ref), but may occur more rapidly (usually within 1 to 4 days) upon reexposure (Ref).

Hepatotoxicity: Varied; median 52 days (range 12 to 89 days) in one study (Ref).

Risk factors:

• Initial dose >100 mg/day (Ref)

• HLA-B*5801 allele is strongly associated with SCARs, especially with comorbid kidney impairment and in some Asian populations (Ref)

• Comorbid kidney impairment correlated to delayed clearance of oxypurinol (metabolite of allopurinol) and potentially high levels of granulysin (Ref)

• Age ≥60 years, possibly due to kidney impairment (Ref)

• Female sex (Ref)

• Asymptomatic hyperuricemia, especially in patients with comorbid kidney impairment or cardiovascular disease (Ref)

• Comorbid cardiovascular disease (Ref)

• Concurrent diuretic use (conflicting data) (Ref)

• Cross-reactivity between allopurinol and febuxostat: Although there may be an increased risk of a skin reaction with febuxostat in patients with a history of reactions to allopurinol, whether this represents 2 separate reactions or cross-reactivity is not known (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Maculopapular rash (≥1%), skin rash (2%)

Gastrointestinal: Diarrhea (≥1%), nausea (1%), vomiting (≤1%)

Hepatic: Increased serum alanine aminotransferase (≥1%), increased serum alkaline phosphatase (≥1%), increased serum aspartate aminotransferase (≥1%)

Neuromuscular & skeletal: Gout (≥1%; acute)

Renal: Kidney failure (≤1%)

<1%:

Cardiovascular: Bradycardia, edema, flushing, heart failure, hypertension, hypotension, low cardiac output, necrotizing angiitis, pericarditis, peripheral vascular disease, pulmonary embolism, thrombophlebitis, vasculitis, vasodilation, ventricular fibrillation

Dermatologic: Alopecia, cellulitis, diaphoresis, ecchymoses, eczema, exfoliative dermatitis, furunculosis, lichen planus, onycholysis, purpuric rash, skin edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vesicobullous dermatitis

Endocrine & metabolic: Albuminuria, decreased libido, gynecomastia, hypercalcemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypernatremia, hyperphosphatemia, hyperuricemia, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lactic acidosis, metabolic acidosis, water intoxication

Gastrointestinal: Abdominal pain, ageusia, anorexia, constipation, dysgeusia, dyspepsia, enlargement of abdomen, enlargement of salivary glands, flatulence, gastritis, gastrointestinal hemorrhage, hemorrhagic pancreatitis, intestinal obstruction, proctitis, stomatitis

Genitourinary: Erectile dysfunction, glycosuria, hematuria, male infertility, oliguria, uremia, urinary tract infection

Hematologic & oncologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, bone marrow depression, chronic myelocytic leukemia, disseminated intravascular coagulation, eosinophilia, eosinophilic fibrohistiocytic bone marrow lesion, hemolytic anemia, hemorrhage, hypoprothrombinemia, leukocytosis, leukopenia, lymphadenopathy, lymphocytosis, neutropenia, pancytopenia, reticulocytosis, splenomegaly, thrombocytopenia, tumor lysis syndrome

Hepatic: Cholestatic jaundice, granulomatous hepatitis, hepatic failure, hepatic necrosis, hepatomegaly, hepatotoxicity, hyperbilirubinemia, jaundice

Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms, facial edema, hypersensitivity angiitis, tongue edema

Infection: Infection, sepsis, septic shock

Local: Injection-site reaction

Nervous system: Agitation, amnesia, asthenia, cerebral infarction, cerebrovascular accident, chills, coma, confusion, depression, dizziness, drowsiness, headache, hypotonia, insomnia, malaise, mental status changes, myoclonus, neuritis, pain, paralysis, paresthesia, peripheral neuropathy, seizure, status epilepticus, tremor, twitching, vertigo

Neuromuscular & skeletal: Arthralgia, dystonia, foot-drop, myalgia, myopathy

Ophthalmic: Amblyopia, cataract, conjunctivitis, iritis, macular retinitis, optic neuritis

Otic: Tinnitus

Renal: Nephritis (including interstitial nephritis)

Respiratory: Acute respiratory distress syndrome, apnea, asthma, bronchospasm, epistaxis, pharyngitis, respiratory failure, rhinitis, tachypnea

Miscellaneous: Fever

Postmarketing:

Dermatologic: Sweet syndrome (Ref)

Hematologic & oncologic: Pure red cell aplasia (Ref)

Hepatic: Cholestatic hepatitis (Ref)

Hypersensitivity: Hypersensitivity reaction (allopurinol hypersensitivity syndrome; can be severe hypersensitivity reaction) (Ref)

Contraindications

Severe hypersensitivity reaction to allopurinol or any component of the formulation.

Canadian labeling: Additional contraindications (not in the US labeling): Breastfeeding mothers and children (except those with cancer therapy-induced hyperuricemia or Lesch-Nyhan syndrome).

Note: To avoid the risk of severe cutaneous adverse reactions (SCAR), HLA-B*5801-positive patients should avoid allopurinol (Perez-Ruiz 2022; Saito 2016). The American College of Rheumatology recommends HLA-B*5801 screening in patients at elevated risk of SCAR, including patients of Asian (eg, Korean, Han Chinese, Thai) and African descent (ACR [FitzGerald 2020a]).

Warnings/Precautions

Concerns related to adverse effects:

• CNS effects: May occasionally cause drowsiness; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).

Disease-related concerns:

• Renal impairment: Dose reductions are recommended in patients with renal impairment; monitor closely. Some patients with preexisting renal disease or poor urate clearance have shown a rise in BUN with allopurinol. Patients with renal impairment should be carefully monitored during the early stages of allopurinol treatment; reduce the dose or withdraw therapy if increased renal function abnormalities appear and persist. Renal failure associated with allopurinol has been observed in patients with hyperuricemia secondary to neoplastic diseases. Concurrent conditions including multiple myeloma and congestive myocardial disease were present among patients whose renal dysfunction increased after allopurinol was begun. Renal failure is also frequently associated with gouty nephropathy. Albuminuria has been observed among patients who developed clinical gout following chronic glomerulonephritis and chronic pyelonephritis.

Other warnings/precautions:

• Hydration: For tumor lysis syndrome prevention, administer aggressive fluids sufficient to maintain adequate hydration and urinary output (Coiffier 2008). For other indications, fluid intake sufficient to yield a daily urinary output of at least 2 L and maintenance of a neutral or (preferably) a slightly alkaline urine are desirable in order to avoid possible formation of xanthine calculi due to allopurinol therapy and to help prevent renal urate precipitation in patients receiving concomitant uricosuric agents.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution Reconstituted, Intravenous, as sodium [strength expressed as base]:

Generic: 500 mg (1 ea)

Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]:

Aloprim: 500 mg (1 ea)

Generic: 500 mg (1 ea)

Tablet, Oral:

Zyloprim: 100 mg [DSC] [scored]

Zyloprim: 300 mg [DSC] [scored; contains corn starch, fd&c yellow #6(sunset yellow)alumin lake]

Generic: 100 mg, 200 mg, 300 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (Allopurinol Sodium Intravenous)

500 mg (per each): $3,480.00 - $4,680.00

Solution (reconstituted) (Aloprim Intravenous)

500 mg (per each): $4,784.47

Tablets (Allopurinol Oral)

100 mg (per each): $0.13 - $0.48

200 mg (per each): $5.55 - $7.95

300 mg (per each): $0.25 - $0.92

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 100 mg, 200 mg, 300 mg

Extemporaneous Preparations

20 mg/mL Oral Suspension:

A 20 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus or a 1:4 mixture of cherry syrup concentrate and simple syrup, NF. Crush eight 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to almost 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label “shake well.” Stable for 60 days refrigerated or at room temperature (Allen 1996; Nahata 2004).

Allen LV Jr, Erickson MA 3rd. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996;53(16):1944-1949.8862208
Nahata MC, Pai VB, Hipple TF. Pediatric Drug Formulations. 5th ed. Cincinnati, OH: Harvey Whitney Books Co; 2004.
Administration: Pediatric

Note: Fluid intake should be sufficient to yield neutral or slightly alkaline (preferably) urine and urine output of at least 100 mL/m2/hour. For tumor lysis syndrome prevention, administer aggressive fluids sufficient to maintain adequate hydration and urinary output; whenever possible, allopurinol therapy should be initiated at least 24 to 48 hours before the start of chemotherapy (and other treatments) known to cause tumor lysis (Ref).

Oral: Administer after meals.

Parenteral: The rate of infusion is dependent upon the volume of the infusion; infuse maximum single daily doses (600 mg/day) over ≥30 minutes.

Administration: Adult

Oral: Administer after meals.

IV: The rate of infusion depends on the volume of the infusion. IV daily dose can be administered as a single infusion or in equally divided doses at 6-, 8-, or 12-hour intervals (Ref).

Tumor lysis syndrome prevention: Administer aggressive fluids sufficient to maintain adequate hydration and urinary output; whenever possible, allopurinol therapy should be initiated 24 to 48 hours before the start of chemotherapy (and other treatments) known to cause tumor lysis (Ref).

Other indications: Administer fluids sufficient to yield daily urinary output of at least 2 L and to maintain a neutral or, preferably, slightly alkaline urine.

Storage/Stability

Powder for injection: Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Following preparation, IV solutions in NS or D5W should be stored at 20°C to 25°C (68°F to 77°F). Do not refrigerate reconstituted and/or diluted product. Must be administered within 10 hours of solution preparation.

Tablet: Store at 15°C to 25°C (59°F to 77°F). Store in a dry place. Protect from light.

Use

Oral: Management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies (FDA approved in pediatric patients [age not specified] and adults); management of primary or secondary gout (acute attack, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) (FDA approved in adults); management of recurrent calcium oxalate calculi (with uric acid excretion >800 mg/day in men and >750 mg/day in women) (FDA approved in adults); has also been used for management of hepatotoxicity, non-hepatic GI toxicity, and inadequate myelosuppression associated with 6-mercaptopurine maintenance therapy for acute lymphoblastic leukemia; treatment of hyperuricemia associated with inborn errors of purine metabolism (Lesch-Nyhan syndrome) and recurrent calcium oxalate calculi associated with glycogen storage disease.

IV: Management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies who cannot tolerate oral therapy (FDA approved in children and adults).

Medication Safety Issues
Sound-alike/look-alike issues:

Allopurinol may be confused with Apresoline

Zyloprim may be confused with zolpidem, ZORprin, Zovirax

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Aluminum Hydroxide: May decrease serum concentration of Allopurinol. Management: Consider administering allopurinol 3 hours prior to aluminum hydroxide. Risk D: Consider Therapy Modification

Amoxicillin: Allopurinol may increase hypersensitivity effects of Amoxicillin. Risk C: Monitor

Ampicillin: Allopurinol may increase hypersensitivity effects of Ampicillin. Risk C: Monitor

Angiotensin-Converting Enzyme Inhibitors: May increase hypersensitivity effects of Allopurinol. Risk C: Monitor

AzaTHIOprine: Allopurinol may increase active metabolite exposure of AzaTHIOprine. More specifically, allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides. Management: Reduce azathioprine dose to one third to one quarter of the usual dose if used with allopurinol, and monitor closely for systemic toxicity. Further dose reduction or alternative therapies should be considered for patients with low or absent TPMT activity. Risk D: Consider Therapy Modification

Bacampicillin: Allopurinol may increase hypersensitivity effects of Bacampicillin. Risk C: Monitor

Bendamustine: Allopurinol may increase adverse/toxic effects of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced. Risk C: Monitor

CycloPHOSphamide: Allopurinol may increase serum concentration of CycloPHOSphamide. Risk C: Monitor

CycloSPORINE (Systemic): Allopurinol may increase serum concentration of CycloSPORINE (Systemic). Risk C: Monitor

Didanosine: Allopurinol may increase serum concentration of Didanosine. Risk X: Avoid

Doxofylline: Allopurinol may increase serum concentration of Doxofylline. Risk C: Monitor

Fluorouracil Products: Allopurinol may decrease active metabolite exposure of Fluorouracil Products. Risk X: Avoid

Loop Diuretics: May increase adverse/toxic effects of Allopurinol. Loop Diuretics may increase serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. Risk C: Monitor

Mercaptopurine: Allopurinol may increase serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides. Management: Reduce the mercaptopurine dose to one third to one quarter of the usual dose if used with allopurinol, and monitor closely for systemic toxicity. Risk D: Consider Therapy Modification

Pegloticase: Allopurinol may increase adverse/toxic effects of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions. Risk X: Avoid

Riluzole: Allopurinol may increase adverse/toxic effects of Riluzole. Specifically, the risk of hepatotoxicity may be increased. Management: Consider alternatives to allopurinol in patients receiving treatment with riluzole due to the potential for additive hepatotoxicity. Risk D: Consider Therapy Modification

Theophylline Derivatives: Allopurinol may increase serum concentration of Theophylline Derivatives. Risk C: Monitor

Thiazide and Thiazide-Like Diuretics: May increase hypersensitivity effects of Allopurinol. Risk C: Monitor

Vitamin K Antagonists: Allopurinol may increase anticoagulant effects of Vitamin K Antagonists. Management: Monitor for increased prothrombin times (PT)/therapeutic effects of oral anticoagulants if allopurinol is initiated/dose increased, or decreased effects if allopurinol is discontinued/dose decreased. Reductions in coumarin dosage will likely be needed. Risk D: Consider Therapy Modification

Dietary Considerations

For tumor lysis syndrome prevention, administer aggressive fluids sufficient to maintain adequate hydration and urinary output (Coiffier 2008). For other indications, fluid intake should be administered to yield neutral or slightly alkaline urine and an output of ~2 L (in adults).

Pregnancy Considerations

Allopurinol crosses the placenta.

Following a single dose of allopurinol 500 mg IV immediately prior to delivery, allopurinol and the oxypurinol metabolite were present in cord blood (Kaandorp 2014; Torrance 2009).

Outcome data following maternal use of allopurinol in pregnancy are limited. Based on similar adverse outcomes from 2 case reports, use during the first trimester is generally avoided until additional data are available. Close maternal and fetal monitoring is recommended when treatment with allopurinol is needed (El-Sonbaty 2001; Hoeltzenbein 2013; Jones 2021; Laube 2021; Patel 2022; Serikawa 2011; Sheikh 2015; Simsek 2018; van Veen 2015).

Monitoring Parameters

CBC, serum uric acid levels, liver function tests, kidney function (hydration status, BUN, serum creatinine), signs and symptoms of cutaneous hypersensitivity; consider HLA-B*5801 testing prior to initiation of therapy in patients at a higher risk for allopurinol hypersensitivity syndrome (ACR [Khanna 2012]).

Mechanism of Action

Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid. Allopurinol is metabolized to oxypurinol which is also an inhibitor of xanthine oxidase; allopurinol acts on purine catabolism, reducing the production of uric acid without disrupting the biosynthesis of vital purines.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

Gout: Decrease in serum and urine uric acid: 2 to 3 days; peak effect: 1 week or longer; normal serum urate levels achieved typically within 1 to 3 weeks.

Cancer therapy-induced hyperuricemia: Median time to plasma uric acid control: 27 hours (Cortes 2010).

Absorption: Oral: 90% from GI tract.

Distribution: Vss: ~0.87 ± 0.13 L/kg.

Metabolism: Rapidly oxidized via the liver to active metabolites, primarily oxypurinol.

Bioavailability: ~49% to 53%.

Half-life elimination:

Oral: Parent drug: ~1 to 2 hours; Oxypurinol: ~15 hours.

IV: Parent drug: 1.21 ± 0.33 hours; Oxypurinol: 23.5 ± 4.5 hours.

Time to peak, plasma: Oral: Allopurinol: 1.5 hours; Oxypurinol: 4.5 hours.

Excretion: Urine (76% as oxypurinol, 12% as unchanged drug); feces (~20%).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Cellidrin | Mephanol | No uric | Novauric | Zyloric;
  • (AR) Argentina: Alfadiman | Alloboxal | Allopurinol craveri | Allopurinol craveri retard | Allopurinol fabra | Allopurinol gador | Allopurinol gador retard | Allopurinol gen me | Allopurinol hexal | Allopurinol Houde | Allopurinol inca | Allopurinol lacefa | Allopurinol phoenix | Alopurinol | Alopurinol fabra | Gotir | Puritenk | Uroquad;
  • (AT) Austria: Allopurinol +pharma | Allopurinol accord | Allopurinol aristo | Allopurinol g.l. | Allopurinol genericon | Allopurinol hexal pharma | Allopurinol sandoz | Allostad | Allotyrol | Gewapurol | Gichtex | Purinol | Urosin | Zyloric;
  • (AU) Australia: Allohexal | Allopurinol-bc | Allorin | Allosig | Apo allopurinol | Chem mart allopurinol | Cm allopurinol | Genrx Allopurinol | Noumed allopurinol | Progout | Sbpa allopurinol | Terry white chemists allopurinol | Tw allopurinol | Zyloprim;
  • (BD) Bangladesh: Alurol | Duric | Esloric | Milurit | Purinol | Ucorex | Zyloric;
  • (BE) Belgium: Allopurinol bexal | Allopurinol eurogenerics | Allopurinol ratiopharm | Allopurinol sandoz | Allopurinol Teva | Docallopu | Zyloric;
  • (BF) Burkina Faso: Allopurinol sandoz | No uric | Zyloric;
  • (BG) Bulgaria: Alodagra | Alopurinol | Lodiric | Milurit;
  • (BR) Brazil: Alopurimilium | Alopurinol | Labopurinol | Lopurax | Zilopur | Zyloric;
  • (CH) Switzerland: Allo-basan | Allopur | Allopurinol 1 A Pharma | Allopurinol Adico | Allopurinol Helvepharm | Allopurinol mepha | Allopurinol Teva | Allopurinol zentiva | Allopurinol-cophar | Cellidrin | Mephanol | Uriconorm | Zyloric;
  • (CI) Côte d'Ivoire: Allopurinol hakim | Allopurinol sandoz | No uric | Zyloric;
  • (CL) Chile: Alopurinol | Dropinol | Talol | Urogotan A | Zyloric;
  • (CN) China: Milurit | Sai bao | Valeric | Zyloric;
  • (CO) Colombia: Allo | Alopurinol | Uralo | Urocuad | Zyloprim | Zyloric;
  • (CY) Cyprus: Sadapron;
  • (CZ) Czech Republic: Allopurinol | Allopurinol apotex | Allospes | Alopurinol | Alopurinol glenmark | Alopurinol sandoz | Apo allopurinol | Milurit | Purinol | Zyloric;
  • (DE) Germany: Allo | Allo-300-tablinen | Allobeta | Allopurinol aristo | Allopurinol Dura | Allopurinol heumann | Allopurinol hexal | Allopurinol indoco | Allopurinol sandoz | Allowieb | Bleminol | Cellidrin | Dura al | Epidropal | Foligan | Jenapurinol | Milurit | Pureduct | Uribenz | Uripurinol | Urtias | Zyloric;
  • (DO) Dominican Republic: Alo-Uril | Alomaron | Alopurinol | Alositol | Gotapurin | Lopurin | Lufrapurinol | Utrisan | Zurim | Zyloprin;
  • (EC) Ecuador: Alopurinol | Alupim | Cristalux | Mefanol | Singota | Urosin | Zyloprim;
  • (EE) Estonia: Allopurinol accord | Allopurinol alpharma | Allopurinol ratiopharm | Allopurinol sandoz | Allopurinool ns | Alopurinol generis | Milurit | Purinol | Zyloric;
  • (EG) Egypt: Crystasol | High Pure | Lessuric | No uric | Purinol | Uric-pure | Zyloric;
  • (ES) Spain: Alopurinol aristo | Alopurinol aurovitas | Alopurinol bluefish | Alopurinol Cinfa | Alopurinol faes | Alopurinol mundogen | Alopurinol normon | Alopurinol Pensa | Alopurinol Ratiopharm | Alopurinol tecnigen | Zyloric;
  • (FI) Finland: Allonol | Allopurinol accord | Allopurinol mylan | Allopurinol orion | Allopurinol tika | Apurin | Apurin sandoz | Arturic | Diatrin | Zyloric;
  • (FR) France: Allopurinol Almus | Allopurinol arrow | Allopurinol Biogaran | Allopurinol gnr | Allopurinol Isomed | Allopurinol merck | Allopurinol phr | Allopurinol Ranbaxy | Allopurinol ratiopharm | Allopurinol RPG | Allopurinol sandoz | Allopurinol Teva | Allopurinol zydus | Zyloric;
  • (GB) United Kingdom: Abbopurin | Allopurinol Almus | Allopurinol arrow | Allopurinol berk | Allopurinol cox | Allopurinol dc | Allopurinol kent | Allopurinol sandoz | Aloral | Aluline | Caplenal | Cosuric | Hamarin | Ledopur | Rimapurinol | Uricto | Xanthomax | Zyloric;
  • (GR) Greece: Petrazyc | Soluric | Stradumel | Zylapour | Zyloric;
  • (HK) Hong Kong: Allopin | Allopranol | Allopurinol Teva | Alloric | Allorin | Apo allopurinol | Clint | Eformat allopurinol | Esloric | Marinol | Mephanol | Milurit | Progout | Puricos | Purinol | Synorid | Synpurinol | Zyloric;
  • (HR) Croatia: Alopurinol | Alopurinol Belupo | Alopurinol PharmaS | Alopurinol sandoz;
  • (HU) Hungary: Allopurinol mylan | Huma-purol | Milapur | Milurit | Zyloric;
  • (ID) Indonesia: Algut | Allonatt | Alluric | Alodan | Alofar | Anuric | Benoxuric | Decasurik | Hycemia | Isoric | Licoric | Linogra | Llanol | Merzaluric | Nilapur | Omeric | Pritanol | Proxuric | Puricemia | Reucid | Sinoric | Tylonic | Urica | Uricnol | Uroquad | Zyloric;
  • (IE) Ireland: Allopurinol actavis | Allopurinol gerard | Allopurinol Teva | Alopur | Caplenal | Purinol | Tipuric | Zyloric;
  • (IL) Israel: Alloril | Zylol;
  • (IN) India: Allgoric | Alloric | Aloric | Ciploric | Gudloric | Lodiric | Logout | Louric | Piloric | Riloric | Swiloric | Uricare | Uriclear | Uritas | Xylor | Zyloric | Zyprinol | Zyrik;
  • (IQ) Iraq: Hyporic;
  • (IT) Italy: Allopurinolo | Allopurinolo Accord | Allopurinolo doc generici | Allopurinolo mylan | Allopurinolo pensa | Allopurinolo San | Allurit | Zyloric;
  • (JO) Jordan: Mephanol | Purinol | Zanuric | Zyloric;
  • (JP) Japan: Adenock | Aframin | Aideito | Allopurinol amel | Allopurinol ayumi | Allopurinol kowa | Allopurinol kyorin | Allopurinol merck | Allopurinol mita | Allopurinol nihon generic | Allopurinol nissin | Allopurinol sawai | Allopurinol showa | Allopurinol tck | Allopurinol Wyeth | Allopurinol Yoshindo | Allorin | Allozym | Aloc hexal | Aloc kaken | Alositol | Anoprolin | Anzief | Aprinol | Arythmet | Ketanrift | Ketanrift teikoku | Ketobun a hisamitsu | Ketobun a isei | Lopuric | Masaton | Miniplanor | Monarch | Neufan | Neufan merck hoei | Neufan nikken | Prodec | Riball | Salobel | Takanarumin takata | Tanabe | Uric | Zyloric;
  • (KE) Kenya: Aleze | G out | Logout | Stradumel | Zyloric;
  • (KR) Korea, Republic of: Epuril | Yuyu allopurinol | Yuyuallopurinol | Zyloric;
  • (KW) Kuwait: Loric | No uric | Zyloric;
  • (LB) Lebanon: Allopurinol Biogaran | Allopurinol genericon | Aluric | Apo allopurinol | Loric | Purinol | Zyloric;
  • (LT) Lithuania: Allo ct | Allopurinol accord | Allopurinol bp | Apo allopurinol | Milurit | Purinol | Zyloric;
  • (LU) Luxembourg: Allpargin | Urosin | Zyloric;
  • (LV) Latvia: Allo ct | Allopurinol accord | Allopurinol sandoz | Allupol | Apo allopurinol | Mephanol | Milurit | Purinol | Zyloric;
  • (MA) Morocco: Lysopuric | Zyloric;
  • (MX) Mexico: Acyprin | Alopurinol | Alopurinol brissa | Alopurinol gi prot | Alopurinol ultra | Alzoprim | Apo tinole | Arramplor | Atisuril | Aurigen | Bionol | Blocco | Darzune | Dertrifort | Etindrax | Genozyl | Puribel | Unizuric | Zyloprim;
  • (MY) Malaysia: Allo | Allopurinol Pharmaniaga | Allopurinol YSP | Apo allopurinol | Clint | Hovid allopurinol | Mephanol | Purinol | Safurinol | Urinol | Zyloric;
  • (NG) Nigeria: Multichris allopurinol;
  • (NL) Netherlands: Acepurin | Allopurinol accord | Allopurinol aristo | Allopurinol CF | Allopurinol nyco | Allopurinol-gf | Apurin | Zyloric;
  • (NO) Norway: Allopur | Allopurinol aristo | Allopurinol orion | Allopurinol ratiopharm | Allopurinol sandoz | Apurin | Arturic | Zyloric;
  • (NZ) New Zealand: Allohexal | Allopurinol apotex | Allorin | Apo allopurinol | Dp allopurinol | Noumed allopurinol | Progout | Zyloprim;
  • (PE) Peru: Alopurinol | Gotapurin | Zyloric | Zyngot;
  • (PH) Philippines: Allocor | Allopurinol Pacific | Allopurinol sandoz | Allujen | Alluprex | Allurase | Alpurase | Alpurin | Alunlan | Aluprin | Boie allopurinol | Dli allopurinol | Elavil | Goutrol | Kylourid | Llanol | Lopric | Lopurine | Loric | Loricid | Purinase | Purispec | Puristen | Synol | Trianol | Urisol | Zyloprim;
  • (PK) Pakistan: Urik | Zyloric | Zynol;
  • (PL) Poland: Allupol | Apo allopurinol | Argadopin | Dnor | Milurit | Zyloric;
  • (PR) Puerto Rico: Aloprim | Zyloprim;
  • (PT) Portugal: Alopurinol | Alopurinol aristo | Alopurinol generis | Alopurinol Labesfal | Alopurinol mylan | Alopurinol Ratiopharm | Alosfar | Ikynol | Uriprim | Zurim | Zyloric;
  • (PY) Paraguay: Allopurinol dallas | Allopurinol dutriec | Alopurinol caplin point | Alopurinol mintlab | Mensil | Uraxin | Uripox | Zyloprim;
  • (QA) Qatar: Aloprim | Goutex (JOSWE) | Loric | No-Uric | Purinol | Zyloric;
  • (RO) Romania: Allopurinol belupo | Alopron | Alopurinol arena | Gichtex;
  • (RU) Russian Federation: Allopurinol egis | Apo allopurinol | Milurit | Purinol | Zyloric;
  • (SA) Saudi Arabia: Apo allopurinol | Apurol | Loric | No uric | Purinol | Zyloric;
  • (SE) Sweden: Allopurinol accord | Allopurinol aristo | Allopurinol Nordic drugs | Allopurinol Nycomed | Allopurinol orion | Allopurinol sandoz | Allopurinol Teva | Zyloric;
  • (SG) Singapore: Allorin | Apo allopurinol | Erloric | Progout | Zyloric;
  • (SI) Slovenia: Alopurinol | Alopurinol Belupo | Alopurinol sandoz | Zyloric;
  • (SK) Slovakia: Alopurinol sandoz | Apo allopurinol | Milurit;
  • (SR) Suriname: Allopurinol apotex | Alopron | Apo allopurinol | Esloric;
  • (TH) Thailand: Alinol | Allonol | Allopin | Alloric | Alloscan | Allostar | Alomet | Apnol | Apurin | Apurinol | Apurol | Burinol | Chinnol | Dicarinol | Lanol | Lolinol | Loporic | Lopurin | Louric | Medoric | Mephanol-100 | Mephanol-300 | Pipallo | Puride | Purinol | Sigapurol | Sinoric | Uratic | Uricad | Valeric | Xandase | Xanol | Zanuric | Zylomed | Zylona | Zylonol | Zyloric | Zyrinol;
  • (TN) Tunisia: Alloric | Purinol | Zyloric;
  • (TR) Turkey: Allo urik | Allogut | Antigut;
  • (TW) Taiwan: A p n | Adeno | Aideito | Alloprim | Allopurine | Alloric | Allorin | Alloscan | Aloprinol | Alputon | Anpurin | Apinol | Apo allopurinol | Aprinol | Apurin | Apurol | Cellidrin | Clint | Enpurol | Gouric | Gylonol | Ketanrift | Kylourid | Purinol | Salobel | Synorid | Tonsaric | Uranid | Urecin | Urinol | Urosin | Xylonol | Zyloric;
  • (UA) Ukraine: Allopurinol lugal | Allopurinol sandoz | Purinol;
  • (UG) Uganda: Stradumel;
  • (UY) Uruguay: Allofed | Allopurinol efa | Allopurinol lazar | Allopurinol Szabo | Goturico | Gulinol S | Zyloric;
  • (VE) Venezuela, Bolivarian Republic of: Alopurinol | Aluprol | Aluron | Mensil | Purinol | Zyloric;
  • (VN) Viet Nam: Allopsel | Angut | Apuric | Inaloric | Urictab | Zuryk;
  • (ZA) South Africa: ADCO allopurinol | Allopurinol unicorn | Austell allopurinol | Lessuric | Lonol | Puricos | Purinol | Ranpuric | Rolab-allopurinol | Urinol | Zorikos | Zyloprim;
  • (ZM) Zambia: Purinol;
  • (ZW) Zimbabwe: Purinol
  1. Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol. 2017;177(5):1234-1247. doi:10.1111/bjd.15423 [PubMed 28256714]
  2. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med. 1981;95(5):588-590. doi:10.7326/0003-4819-95-5-588 [PubMed 7294548]
  3. Allen LV, Erickson MA 3rd. Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids. Am J Health Syst Pharm. 1996;53(16):1944-1949. [PubMed 8862208]
  4. Allopurinol tablet [prescribing information]. East Brunswick, NJ: Rising Pharma Holdings Inc; April 2023.
  5. Allopurinol tablet [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; April 2024.
  6. Aloprim (allopurinol) injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC; February 2022.
  7. Alotaibi T, Bjazevic J, Kim R, et al. Allopurinol hypersensitivity syndrome raising awareness of an uncommon but potentially serious adverse event among kidney stone patients. Can Urol Assoc J. 2024;18(5):E167-E172. doi:10.5489/cuaj.8685 [PubMed 38319608]
  8. Appelbaum SJ, Mayersohn M, Dorr RT, et al. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol. 1982;8(1):93-98. [PubMed 7094203]
  9. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007.
  10. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504-2513. doi:10.1056/NEJMoa1915833 [PubMed 32579811]
  11. Bardin T, Chalès G, Pascart T, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314-317. doi:10.1016/j.jbspin.2015.07.011 [PubMed 26709250]
  12. Barone T, Dandekar S, McKeone D, Mulieri K. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with acute lymphoblastic leukemia and lymphoma during maintenance therapy. Cancer Rep (Hoboken). 2024;7(2):e1987. doi:10.1002/cnr2.1987 [PubMed 38351548]
  13. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. doi:10.1080/15257770802136032 [PubMed 18600509]
  14. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461. doi:10.1056/NEJMoa050373 [PubMed 16339094]
  15. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  16. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432. [PubMed 15570646]
  17. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  18. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966. [PubMed 24935270]
  19. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259 [PubMed 33929376]
  20. Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo WA. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum. 1977;20(8):1546-1549. doi:10.1002/art.1780200817 [PubMed 921828]
  21. Chen IH, Kuo MC, Hwang SJ, Chang JM, Chen HC. Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J Med Sci. 2005;21(5):228-232. doi:10.1016/S1607-551X(09)70192-5 [PubMed 15960069]
  22. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12):1373-1379. doi:10.1001/archdermatol.2010.198 [PubMed 20713773]
  23. Childs L, Dow C. Allopurinol-induced hepatomegaly. BMJ Case Rep. 2012;bcr2012007283. doi:10.1136/bcr-2012-007283 [PubMed 23087287]
  24. Choi HG, Byun J, Moon CH, et al. Allopurinol-induced DRESS syndrome mimicking biliary obstruction. Clin Mol Hepatol. 2014;20(1):71-75. doi:10.3350/cmh.2014.20.1.71 [PubMed 24757661]
  25. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157-2164. doi:10.1136/annrheumdis-2014-205577 [PubMed 25115449]
  26. Cohen G, Cooper S, Sison EA, Annesley C, Bhuiyan M, Brown P. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity. Pediatr Blood Cancer. 2020;67(11):e28360. doi:10.1002/pbc.28360 [PubMed 32909665]
  27. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26(16):2767-2778. [PubMed 18509186]
  28. Copelovitch L. Urolithiasis in children: medical approach. Pediatr Clin North Am. 2012;59(4):881-896. [PubMed 22857835]
  29. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uria acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213. [PubMed 20713865]
  30. Curhan GC. Kidney stones in adults: prevention of recurrent kidney stones. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 6, 2024a.
  31. Curhan GC. Kidney stones in adults: uric acid nephrolithiasis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 6, 2024b.
  32. Currie WJ, Turmer P, Young JH. Evaluation of once a day allopurinol administration in man. Br J Clin Pharmacol. 1978;5(1):90-91. [PubMed 619943]
  33. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391-395. [PubMed 17897242]
  34. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623-644. doi:10.2165/00003088-200746080-00001 [PubMed 17655371]
  35. Day RO, Kannangara DR, Hayes JM, Furlong TJ. Successful use of allopurinol in a patient on dialysis. BMJ Case Rep. 2012;2012:bcr0220125814. doi:10.1136/bcr.02.2012.5814 [PubMed 22675142]
  36. Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG. Allopurinol: insights from studies of dose-response relationships. Expert Opin Drug Metab Toxicol. 2017;13(4):449-462. doi:10.1080/17425255.2017.1269745 [PubMed 27927043]
  37. El-Sonbaty MR, Bitar Z, Abdulrazak A. Acute spontaneous tumor-lysis syndrome in a pregnant woman with non-Hodgkin's lymphoma. Int J Hematol. 2001;73(3):386-389. doi:10.1007/BF02981967 [PubMed 11345208]
  38. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386-1389. doi:10.1056/NEJM198611273152204. [PubMed 3534570]
  39. Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
  40. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020a;72(6):744-760. doi:10.1002/acr.24180 [PubMed 32391934]
  41. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol. 2020b;72(6):879-895. doi:10.1002/art.41247 [PubMed 32390306]
  42. FitzGerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. Arthritis Care Res (Hoboken). 2018;70(5):659-671. doi:10.1002/acr.23500 [PubMed 29649348]
  43. Fontana RJ, Li YJ, Phillips E, et al. Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver Int. 2021;41(8):1884-1893. doi:10.1111/liv.14903 [PubMed 33899326]
  44. Gahart BL, Nazareno AR. 2012 Intravenous Medications: A Handbook for Nurses and Health Professionals. 28th ed. Elsevier/Mosby; 2012:58-59.
  45. Gelbart DR, Weinstein AB, Fajardo LF. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86(2):196-198. doi:10.7326/0003-4819-86-2-196 [PubMed 835946]
  46. Gupta SS, Sabharwal N, Patti R, Kupfer Y. Allopurinol-induced Stevens-Johnson syndrome. Am J Med Sci. 2019;357(4):348-351. doi:10.1016/j.amjms.2018.11.018 [PubMed 30638600]
  47. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56. doi:10.1016/0002-9343(84)90743-5 [PubMed 6691361]
  48. Hayes CP Jr, Metz EN, Robinson RR, Rundles RW. The use of allopurinol (HPP) to control hyperuricemia in patients on chronic intermittent hemodialysis. Trans Am Soc Artif Intern Organs. 1965;11:247-254. doi 10.1097/00002480-196504000-00047 [PubMed 14329092]
  49. Heilberg IP. Treatment of patients with uric acid stones. Urolithiasis. 2016;44(1):57-63. doi:10.1007/s00240-015-0843-8 [PubMed 26645868]
  50. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153-158. [PubMed 23232549]
  51. Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity. PLoS One. 2013;8(6):e66637. doi:10.1371/journal.pone.0066637 [PubMed 23840514]
  52. Hoyer D, Atti C, Nuding S, Vogt A, Sedding DG, Schott A. Toxic epidermal necrolysis caused by allopurinol: a serious but still underestimated adverse reaction. Am J Case Rep. 2021;22:e932921. doi:10.12659/AJCR.932921 [PubMed 34634004]
  53. Hug BL, Surber C, Bates DW. Use of hepatotoxic drugs in chronic liver disease. J Patient Saf. 2012;8(2):45-50. doi:10.1097/PTS.0b013e3182482df2 [PubMed 22525363]
  54. Imai H, Kamei H, Onishi Y, et al. Successful living-donor liver transplantation for cholestatic liver failure induced by allopurinol: case report. Transplant Proc. 2015;47(9):2778-2781. doi:10.1016/j.transproceed.2015.09.038 [PubMed 26680093]
  55. Iqbal U, Siddiqui HU, Anwar H, Chaudhary A, Quadri AA. Allopurinol-induced granulomatous hepatitis: a case report and review of literature. J Investig Med High Impact Case Rep. 2017;5(3):2324709617728302. doi:10.1177/2324709617728302 [PubMed 29082266]
  56. Jennings CG, Mackenzie IS, Flynn R, et al; FAST study group. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25-30. doi:10.1016/j.semarthrit.2014.01.004 [PubMed 24560169]
  57. Jones AM, Tower C, Green D, Stepien KM. Multidisciplinary management of pregnancy and labour in a patient with glycogen storage disease type 1a. BMJ Case Rep. 2021;14(8):e241161. doi:10.1136/bcr-2020-241161 [PubMed 34380672]
  58. Kaandorp JJ, van den Broek MP, Benders MJ, et al; ALLO-trial Study Group. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F144-F148. doi:10.1136/archdischild-2013-304876 [PubMed 24352085]
  59. Källström J, Niinimäki R, Fredlund J, et al. Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study. Haematologica. 2024;109(9):2846-2853. doi:10.3324/haematol.2023.284390 [PubMed 38356449]
  60. Kamilli I, Gresser U. Allopurinol and oxypurinol in human breast milk. Clin Investig. 1993;71(2):161-164. doi:10.1007/BF00179999 [PubMed 8461629]
  61. Keller SF, Lu N, Blumenthal KG, et al. Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Ann Rheum Dis. 2018;77(8):1187-1193. doi:10.1136/annrheumdis-2017-212905 [PubMed 29653927]
  62. Kenny JE, Goldfarb DS. Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep. 2010;12(2):125-129. doi:10.1007/s11926-010-0089-y [PubMed 20425021]
  63. Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. [PubMed 23024028]
  64. Larson RA, Pui CH. Tumor lysis syndrome: prevention and treatment. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 18, 2024.
  65. Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53(11):1920-1926. doi:10.1093/rheumatology/keu157 [PubMed 24758886]
  66. Laube R, Paramsothy S, Leong RW. Review of pregnancy in Crohn's disease and ulcerative colitis. Therap Adv Gastroenterol. 2021;14:17562848211016242. doi:10.1177/17562848211016242 [PubMed 34046084]
  67. Lien YH, Logan JL. Cross-reactions between allopurinol and febuxostat. Am J Med. 2017;130(2):e67-e68. doi:10.1016/j.amjmed.2016.08.042 [PubMed 27667702]
  68. Lipkin ME, Preminger GM. Demystifying the medical management of nephrolithiasis. Rev Urol. 2011;13(1):34-38. [PubMed 21826126]
  69. Luo Q, Cai Y, Zhao Q, Tian L, Liu Y, Liu WJ. Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. Ren Fail. 2022;44(1):806-814. doi:10.1080/0886022X.2022.2068443 [PubMed 35856157]
  70. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J. 2005;7(10):656-660. [PubMed 16259349]
  71. Mitra S, Cohen RA. Medical management of uric acid stones. In: Han H, Mutter WP, Nasser S, eds. Nutritional and Medical Management of Kidney Stones. Springer International Publishing; 2019.
  72. Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11(5):343-353. doi:10.2165/00003088-198611050-00001 [PubMed 3536254]
  73. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management of drug allergy in adults, children and young people. https://www.nice.org.uk/guidance/cg183. Published September 2014. Accessed November 19, 2020.
  74. Ng CY, Yeh YT, Wang CW, et al. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373-1381. doi:10.1016/j.jid.2016.02.808 [PubMed 26996548]
  75. Park HJ, Yun J, Kang DY, et al. Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions. J Allergy Clin Immunol Pract. 2019;7(8):2739-2749.e3. doi:10.1016/j.jaip.2019.05.047 [PubMed 31201937]
  76. Patel AV, Gaffo AL. Managing gout in women: current perspectives. J Inflamm Res. 2022;15:1591-1598. doi:10.2147/JIR.S284759 [PubMed 35264868]
  77. Peerapen P, Thongboonkerd V. Kidney stone prevention. Adv Nutr. 2023;14(3):555-569. doi:10.1016/j.advnut.2023.03.002 [PubMed 36906146]
  78. Perez-Ruiz F. Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 19, 2022.
  79. Perissinotti AJ, Bishop MR, Bubalo J, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel. Cancer Treat Rev. 2023;120:102603. doi:10.1016/j.ctrv.2023.102603 [PubMed 37579533]
  80. Polimeni G, Cardillo R, Garaffo E, et al. Allopurinol-induced Sweet's syndrome. Int J Immunopathol Pharmacol. 2016;29(2):329-332. doi:10.1177/0394632015599705 [PubMed 26684631]
  81. Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68. doi:10.7326/M16-0570 [PubMed 27802508]
  82. Quach C, Galen BT. HLA-B*5801 testing to prevent allopurinol hypersensitivity syndrome: a teachable moment. JAMA Intern Med. 2018;178(9):1260-1261. doi:10.1001/jamainternmed.2018.3556 [PubMed 30083702]
  83. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953-980. doi:10.1007/s40264-013-0084-0 [PubMed 23873481]
  84. Raper R, Ibels L, Lauer C, Barnes P, Lunzer M. Fulminant hepatic failure due to allopurinol. Aust N Z J Med. 1984;14(1):63-65. doi:10.1111/j.1445-5994.1984.tb03591.x [PubMed 6590011]
  85. Refer to manufacturer's labeling.
  86. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707 [PubMed 27457514]
  87. Saito Y, Stamp LK, Caudle KE, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-37. doi:10.1002/cpt.161 [PubMed 26094938]
  88. Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. Clin Pediatr (Phila). 1998;37(10):583-599. [PubMed 9793728]
  89. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
  90. Serikawa T, Abe T, Minamikawa T, et al. A case report of fatal tumor lysis syndrome after chemotherapy in a pregnant patient with Burkitt's lymphoma. J Obstet Gynaecol Res. 2011;37(8):1141-1144. doi:10.1111/j.1447-0756.2010.01485.x [PubMed 21481095]
  91. Shankar P, Aish L, Hassoun H. Allopurinol-induced pure red cell aplasia. Am J Hematol. 2003;73(1):69. doi:10.1002/ajh.10315 [PubMed 12701126]
  92. Sheikh M, Nelson-Piercy C, Duley J, Florin T, Ansari A. Successful pregnancies with thiopurine-allopurinol co-therapy for inflammatory bowel disease. J Crohns Colitis. 2015;9(8):680-684. doi:10.1093/ecco-jcc/jjv072 [PubMed 25939351]
  93. Simsek M, Opperman RCM, Mulder CJJ, Lambalk CB, de Boer NKH. The teratogenicity of allopurinol: a comprehensive review of animal and human studies. Reprod Toxicol. 2018;81:180-187. doi:10.1016/j.reprotox.2018.08.012 [PubMed 30125681]
  94. Singh JA, Ramachandaran R, Yu S, Curtis JR. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord. 2017;17(1):76. doi:10.1186/s12872-017-0513-6 [PubMed 28288564]
  95. Singh JA, Yu S. Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol. 2016;16(1):164. doi:10.1186/s12883-016-0692-2 [PubMed 27604082]
  96. Stamp LK, Barclay ML. How to prevent allopurinol hypersensitivity reactions? Rheumatology (Oxford). 2018;57(suppl 1):i35-i41. doi:10.1093/rheumatology/kex422 [PubMed 29272508]
  97. Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12(4):235-242. doi:10.1038/nrrheum.2015.132. Erratum in: Nat Rev Rheumatol. 2016;12(4):i. [PubMed 26416594]
  98. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529-2536. doi:10.1002/art.34488 [PubMed 22488501]
  99. Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019;18(4):261-271. doi:10.1080/14740338.2019.1594771 [PubMed 30915866]
  100. Tassaneeyakul W, Jantararoungtong T, Chen P, et al Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704-709. doi:10.1097/FPC.0b013e328330a3b8 [PubMed 19696695]
  101. Torrance HL, Benders MJ, Derks JB, et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009;124(1):350-357. doi:10.1542/peds.2008-2228 [PubMed 19564319]
  102. Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007a;56(9):1179-1186. [PubMed 17697859]
  103. Torres RJ, Puig JG. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007b;2:48. [PubMed 18067674]
  104. van Veen TR, Haeri S. Gout in pregnancy: a case report and review of the literature. Gynecol Obstet Invest. 2015;79(4):217-221. doi:10.1159/000369999 [PubMed 25660596]
  105. Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70(3):422-439. doi:10.1053/j.ajkd.2017.01.055 [PubMed 28456346]
  106. Wang CW, Dao RL, Chung WH. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Curr Opin Allergy Clin Immunol. 2016;16(4):339-345. doi:10.1097/ACI.0000000000000286 [PubMed 27362322]
  107. World Health Organization. Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
  108. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-2397. doi:10.1016/j.clinthera.2011.01.008 [PubMed 21353107]
  109. Wright DF, Doogue MP, Barclay ML, et al. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol. 2017;73(1):71-78. doi:10.1007/s00228-016-2133-y [PubMed 27683090]
  110. Yang CY, Chen CH, Deng ST, et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175(9):1550-1557. doi:10.1001/jamainternmed.2015.3536 [PubMed 26193384]
  111. Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Intern Med J. 2019;49(7):838-842. doi:10.1111/imj.14163 [PubMed 30426652]
  112. Yokose C, Lu N, Xie H, et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ. 2019;191(39):E1070-E1077. doi:10.1503/cmaj.190339 [PubMed 31570545]
  113. Zyloprim (allopurinol) tablets [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; October 2023.
  114. Zyloprim (allopurinol) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; September 2021.
Topic 13339 Version 609.0